Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

229 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer.
Ricciuti B, Brambilla M, Cortellini A, De Giglio A, Ficorella C, Sidoni A, Bellezza G, Crinò L, Ludovini V, Baglivo S, Metro G, Chiari R. Ricciuti B, et al. Among authors: ficorella c. Clin Transl Oncol. 2020 May;22(5):708-716. doi: 10.1007/s12094-019-02175-y. Epub 2019 Jul 22. Clin Transl Oncol. 2020. PMID: 31332704
Meta-analysis of phase III trials of docetaxel alone or in combination with chemotherapy in metastatic breast cancer.
Belfiglio M, Fanizza C, Tinari N, Ficorella C, Iacobelli S, Natoli C; Consorzio Interuniversitario Nazionale per la Bio-Oncologia (CINBO). Belfiglio M, et al. Among authors: ficorella c. J Cancer Res Clin Oncol. 2012 Feb;138(2):221-9. doi: 10.1007/s00432-011-1091-0. Epub 2011 Nov 18. J Cancer Res Clin Oncol. 2012. PMID: 22095437 Free PMC article. Review.
Effectiveness of liver metastasectomies in patients with metastatic colorectal cancer treated with FIr-B/FOx triplet chemotherapy plus bevacizumab.
Bruera G, Cannita K, Giuliante F, Lanfiuti Baldi P, Vicentini R, Marchetti P, Nuzzo G, Antonucci A, Ficorella C, Ricevuto E. Bruera G, et al. Among authors: ficorella c. Clin Colorectal Cancer. 2012 Jun;11(2):119-26. doi: 10.1016/j.clcc.2011.11.002. Epub 2011 Dec 27. Clin Colorectal Cancer. 2012. PMID: 22206922 Clinical Trial.
Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease.
Bruera G, Cannita K, Di Giacomo D, Lamy A, Troncone G, Dal Mas A, Coletti G, Frébourg T, Sabourin JC, Tosi M, Ficorella C, Ricevuto E. Bruera G, et al. Among authors: ficorella c. BMC Med. 2012 Nov 8;10:135. doi: 10.1186/1741-7015-10-135. BMC Med. 2012. PMID: 23136868 Free PMC article.
The prevalent KRAS exon 2 c.35 G>A mutation in metastatic colorectal cancer patients: A biomarker of worse prognosis and potential benefit of bevacizumab-containing intensive regimens?
Bruera G, Cannita K, Tessitore A, Russo A, Alesse E, Ficorella C, Ricevuto E. Bruera G, et al. Among authors: ficorella c. Crit Rev Oncol Hematol. 2015 Mar;93(3):190-202. doi: 10.1016/j.critrevonc.2014.10.004. Epub 2014 Oct 16. Crit Rev Oncol Hematol. 2015. PMID: 25459669 Review.
229 results